XNCR vs XTLB

Xencor, Inc. vs XTL Biopharmaceuticals Ltd. — Valuation Comparison 2026

XNCR

Biotechnology
Xencor, Inc.
Quality
6.1
out of 10
Value Trap
15
SAFE
Price
$11.97
Last close
Models
9/13
Active
VS

XTLB

Biotechnology
XTL Biopharmaceuticals Ltd.
Quality
1.7
out of 10
Value Trap
Price
$2.46
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType XNCR Fair ValueXNCR Upside XTLB Fair ValueXTLB Upside
Bayesian DCF Intrinsic $1.41 -88.2% $0.65 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.99 -91.2% $1.84 -25.4%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $1.65 -86.2% $0.72 -71.6%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for XNCR vs XTLB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XNCR vs XTLB — Which Stock Is More Undervalued?

XNCR scores higher with a 6.1/10 quality rating vs XTLB's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Xencor, Inc. (XNCR) and XTL Biopharmaceuticals Ltd. (XTLB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XNCR currently trades at $11.97 with a QOC of 6.1/10, while XTLB trades at $2.46 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).